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Abstract
Objectives—In adults with unexplained pancreatitis, the yield of complete gene versus select 
exosome sequencing on mutation detection and distinguishing clinical characteristics associated 
with mutations requires clarification. We sought to: 1) compare frequency of mutations identified 
using difference techniques and 2) compare clinical characteristics between adults with and 
without mutations.
Methods—Cohort study of adults with unexplained pancreatitis who underwent genetic testing 
between 1/2008-12/2012. We compare probabilities of having a positive mutation with complete 
gene sequencing versus alternatives, and describe differences in characteristics among patients 
with and without mutations.
Results—Of 370 patients, 67 (18%) had a genetic mutation; 24 (6%) were high-risk. Mutations 
were significantly more prevalent with use of complete sequencing (42%) versus other approaches 
(8%, p<0.0001). The majority (44/67, 66%) with a mutation had no family history. Those with 
high-risk mutations were more likely to have and family history of chronic pancreatitis (21% v. 
4%, p=0.002). Patients with pancreas divisum were more likely to have mutations (27% v. 14%, 
p=0.0007).
Conclusion—Among individuals with adult-onset pancreatic disease, the probability of finding 
any mutation, including high-risk, is significantly higher using complete gene sequencing. The 
impact on patients and providers requires further investigation.
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Introduction
Patients with adult onset, idiopathic chronic pancreatitis (CP) and recurrent acute 
pancreatitis (RAP) increasingly undergo testing to evaluate for a genetic predisposition. 
Genes of interest include the cystic fibrosis transmembrane conductance regulator (CFTR), 
the protease serine 1 (PRSS1), the serine protease inhibitor, Kazal type 1 (SPINK1), and 
chymotrypsin C (CTRC).1–18 Inheritance patterns may be autosomal dominant (PRSS1), 
autosomal recessive (CFTR, SPINK1), or complex (e.g., heterozygous CFTR, SPINK1, and 
CTRC); the latter includes gene-environment and gene-gene (i.e., compound heterozygosity) 
interactions.1, 4
It is increasingly recognized that a genetic predisposition to pancreatitis is not limited to a 
pediatric population, as some individuals will develop symptoms during adulthood (age > 18 
years). Among small series of adults with CP or RAP, pancreas divisum has been associated 
with a higher prevalence of genetic mutations.19–21 The clinical significance of a genetic 
mutation as the sole risk factor or covariate with environmental factors (e.g., alcohol and 
smoking) requires clarification.22
Our objectives were two-fold. First, while newer assays utilize complete gene sequence 
analysis, their impact on detecting mutations in an adult population as compared to other 
methods is unclear. We compare the frequency of positive gene mutations identified using 
different assays. Second, since genetic testing is expensive and identifying a mutation (even 
one with unclear clinical significance) may have unintended long-term implications for 
patients (e.g., insurability, anxiety), we sought to identify clinical characteristics associated 
with positive genetic mutations. This may inform clinicians of at-risk groups who would be 
most likely to have a mutation.
Methods
Study Design and Patient Selection
We conducted a retrospective cohort study of all symptomatic adults who underwent 
pancreas-specific genetic testing between January 2008 and December 2012. Patients were 
identified from our pancreatobiliary clinical practice at Indiana University Health University 
Hospital, a tertiary referral center for chronic pancreatitis and other pancreatic disorders. We 
used an institutional review board-approved clinical database that contains prospectively 
entered clinical data. We excluded patients age <18 at the time of genetic testing. The study 
received approval from our local institutional review board prior to the collection of data 
and none of the authors declare any conflict of interests.
The indications for genetic testing included: idiopathic RAP, idiopathic CP, or symptoms 
consistent with CP (e.g., steatorrhea responding to oral pancreatic enzymes, abdominal pain 
consistent with CP). Medical records were abstracted for patient demographics, the presence 
of pancreatitis-related symptoms including abdominal pain (not associated with an episode 
of acute pancreatitis), exocrine insufficiency, endocrine insufficiency and age of symptom 
onset. When available, we recorded specific morphologic abnormalities identified by 
imaging (i.e., computed tomography (CT), magnetic resonance imaging (MRI), endoscopic 
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ultrasound (EUS), and endoscopic retrograde pancreatography (ERCP)): pancreas divisum, 
pancreatic calcifications, and main pancreatic duct stricture/dilated main pancreatic duct, 
among others. We recorded family history of acute pancreatitis, RAP, CP, and pancreatic 
cancer.
Definitions
Acute pancreatitis was defined as acute abdominal pain associated with increased serum 
pancreatic enzyme levels (amylase and/or lipase) > 3 times the upper limit of normal value 
or imaging changes consistent with acute pancreatitis;23 documentation of such findings 
were required in the medical records. RAP was defined as two or more discrete episodes of 
documented acute pancreatitis.24 Patients were diagnosed with CP based on standard 
radiographic criteria, including the presence of pancreatic calcifications on CT, EUS, or 
ERCP; pancreatic ductal abnormalities on pancreatography obtained by magnetic resonance 
cholangiopancreatography (MRCP) or ERCP (using the Cambridge classification); ≥5 
endosonographic criteria on EUS; marked pancreatic atrophy on CT or MRCP; and exocrine 
insufficiency based on a history of steatorrhea.25–28 A diagnosis of pancreas divisum 
required confirmation via ERCP or MRCP.29–31
Genetic Testing
The decision to perform genetic testing was always at the discretion of the treating 
physician. During the study period, we used several third party assays for genetic testing 
(table 1). Since 2011, we have used complete gene sequence analysis (Ambry Genetics) for 
all of our patients. Prior to 2011, several other entities were used: CFTR testing by other 
entities (Genzyme and Quest Diagnostics) used enzymatic amplification of known mutations 
(97 and 32, respectively); PRSS1 testing by other entities (Mayo Clinic and University of 
Pittsburgh Medical Center) employed gene sequence analysis for a smaller portion of the 
gene where mutations were known to impact pancreatitis risk (table 1). For descriptive 
purposes in this study, “complete gene sequencing” refers to assays conducted by Ambry 
Genetics.
We defined a positive genetic test as a mutation detected for any of the 4 genes tested. We 
also present the frequency of high-risk mutations32–34, which we defined as: 1) a single copy 
mutation of PRSS1; 2) homozygous mutations of CFTR, SPINK1 or CTRC; or 3) 
compound heterozygous mutations of CFTR, SPINK1 and/or CTRC.
Analysis Plan
The cohort was dichotomized by the presence of any genetic mutation. Given the clinical 
significance of individuals having mutations known to have high risk for leading to 
pancreatic disease, we also present the characteristics of this subgroup. We used descriptive 
statistics (mean ± standard deviation, proportion with 95% confidence intervals) to present 
patient and phenotypic characteristics. To examine differences between study populations 
(those with any genetic mutation versus all others and those with a high-risk mutation versus 
all others), we used comparative statistics (Student’s t test or Fisher’s exact test) where 
appropriate.
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Results
Prevalence of pancreas-specific genetic mutations
During the five-year study period, we identified 370 symptomatic adults who underwent 
genetic testing through the adult pancreatobiliary practice at Indiana University. Of these, 67 
(18.1%) had a genetic mutation, 24 (6.5%) of which were high-risk (figure 1). A per-patient 
summary of mutations is available (supplementary table). Among patients who underwent 
testing for CFTR (n=359), 109 (30.4%) were via complete gene sequencing (Ambry), 249 
(69.4%) were via enzymatic amplification for 97 mutations (Genzyme), and 1 (0.3%) was 
via enzymatic amplification for 32 mutations (Quest). For PRSS1 mutations (n=267), 106 
(39.7%) were via complete gene sequencing (Ambry) and 161 (60.3%) were via DNA 
sequencing of exons 2 and 3 (Mayo Clinic and University of Pittsburgh). All SPINK1 
(n=107) and CTRC (n=94) assays were performed using complete gene sequencing 
(Ambry).
The probability of a detecting any mutation and a high-risk mutation significantly increased 
when complete gene sequencing was performed (table 2). Patients tested by complete gene 
sequencing had a mutation detected in 42.2% of cases as compared to 8.1% when using any 
other method (p<0.0001). Similarly, patients having a high-risk mutation were identified in 
18.3% of cases using complete gene sequencing versus 1.5% when using other modalities 
(p<0.001). These differences remained significant for the subgroup of individuals tested for 
PRSS1 or CFTR mutations.
Clinical history
The majority (354 of 370, 96%) of patients were Caucasian. There were no significant 
differences in patient characteristics of those with and without genetic mutations (table 3). 
Age of presentation was younger for individuals with high-risk mutations (32.3±15.4, 
p=0.05 vs. all others), although those having no mutations also presented with an average 
age < 40 (39.5±16.1). Patients with high-risk mutations were more likely to report a family 
history of chronic pancreatitis (20.8%, p=0.002 vs. all others), but there was no significant 
difference between those having any mutation (7.6%) and no mutation (3.7%, p=0.18). 
There was a greater likelihood of having a family history of acute pancreatitis among high-
risk individuals, but this did not reach statistical significance (p=0.17). The prevalence of a 
family history of pancreatic cancer was similar in all groups. Importantly, 44 of the 67 
(65.7%) patients with a mutation had no family history of acute pancreatitis, chronic 
pancreatitis or pancreatic cancer. Among those with high-risk mutations (n=24), 14 (58.3%) 
had no family history.
Presenting symptoms (abdominal pain, steatorrhea, diabetes, and weight loss) were similar 
between patients having no mutation and any mutation, including those with a high-risk 
mutation (table 4). Patients with any mutation (67.2%) were more likely to present with 
recurrent acute pancreatitis compared to those without a mutation (47.5%, p=0.004). There 
was no significant difference in the rate of CP when comparing patients with no genetic 
mutation with any genetic mutations (p=0.12) or a high-risk mutation (p=0.13). The 
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prevalence of moderate/severe CP and having a history of a single episode of acute 
pancreatitis was similar among all populations.
Phenotypic characteristics
Despite similarities in age of symptom onset, age of presentation, and clinical history, there 
were important phenotypic differences between those with and without a pancreas-specific 
genetic mutation (table 5). In the entire cohort, there were 59 (15.9%) patients with pancreas 
divisum, of who 48 (81.4%) were diagnosed by ERCP and 11 (18.6%) by MRCP. Patients 
without a mutation were less likely to have pancreas divisum (13.6%) compared to 26.9% of 
those with any mutation (p=0.01) and 33.3% of those with a high-risk mutation (p=0.04). 
This remained significant when the analysis was limited to the subgroup (n=279) that 
underwent ERCP. Pancreatic calcifications and main duct strictures were more frequently 
diagnosed among patients with genetic mutations, particularly those classified as high risk.
Discussion
Genetic mutations among adults with unexplained pancreatic disease
Consistent with previous studies, the prevalence of genetic mutations in a cohort of adult 
individuals with pancreatic disease undergoing genetic testing is substantial 
(18.1%),1–3, 5, 6, 8–11, 13–18 though high-risk mutations are identified less frequently (6.5%). 
Importantly, use of a test that sequences the entire gene(s) of interest identified significantly 
(greater than 5-fold) more mutations, including those classified as high-risk (greater than 12-
fold). Prior studies using genetic sequencing of either the entire gene or a large percentage 
of it have also shown high rates of finding genetic mutations with a 45–49% rate of 
mutations found in the CFTR, PRSS1 and SPINK1 genes in similar patient 
populations.1, 5, 35 Alternative analytics for mutations such as high resolution DNA melting 
may provide rapid and accurate diagnostics at a lower cost.36 Other genetic testing 
modalities utilized in our cohort either sequenced a smaller portion of the gene or used other 
techniques such as enzymatic amplification of predefined mutations. The rate of detected 
mutations in our cohort likely would have been higher if all individuals had undergone gene 
sequence analysis of all 4 genes. The clinical significance and impact of identifying many of 
these mutations will require further clarification and not all mutations identified to date have 
been associated with the development of pancreatic disease. Specifically, counseling of 
patients and relatives, screening for pancreatic cancer and impact of potential therapies (both 
endoscopic and surgical) in patients with genetic mutations and pancreatic disease such as 
chronic pancreatitis will require further investigation. Furthermore, the pathogenic 
significance of some mutations (e.g., c.592-24C>T) is unknown; future studies may impact 
the classification of high-risk and unknown risk mutations presented in this paper.
Clinical factors do not distinguish adults with pancreas-specific genetic mutations
Age of symptom onset, age of clinical presentation, and presenting symptoms were not 
associated with having a genetic mutation; those having a high-risk mutation developed 
overt symptoms in their early 30s (mean age 32) while those with no mutation were in their 
late 30s (mean age 39). Since we limited our analysis to individuals who underwent genetic 
testing, our study is susceptible to a selection bias so this observation should be interpreted 
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with caution: the treating physician suspected a genetic abnormality based on family history, 
age, and/or idiopathic nature of their illness. Nevertheless, these demographic and clinical 
factors were similar among those with and without mutations. Further, the absence of a 
family history in more than half of individuals with a mutation (including those deemed 
high-risk) highlights their variable penetrance: autosomal dominant (minority), autosomal 
recessive (one parent with two mutations or two parents each with a single mutation), and 
complex genetic-environment interactions. Our cohort represents a “real-world” adult 
population that would be considered for genetic testing.
Family history is not a prerequisite for pancreas-specific genetic mutations
Prior studies have shown that 4% of patients with familial (non-autosomal dominant) CP 
have a mutation in the CTRC gene14 and up to 86% have a mutation in the SPINK1 gene12. 
While patients with high-risk mutations in our cohort were more likely to have a family 
history of CP (20.8%), the majority of individuals with high-risk or any mutations had no 
known family history of chronic pancreatitis; therefore, the absence of a family history 
should not dissuade the clinician from pursuing a genetic evaluation.
Previous reports have shown that patients with RAP have an increased rate of mutations in 
the CFTR gene, ranging from 12-32%1, 15, 16, as well as an increased rate of compound 
heterozygosity1. Numerous studies using a variety of methods for genetic testing have 
reported more mutations in patients with CP, including CFTR (18–44%),1, 4–7, 17 PRSS1 
(2%),1 SPINK1 (5–23%),1, 5, 6, 10–12, 18, 37, 38 and CTRC (3–12%).13, 14. In our cohort, 67% 
of patients with a mutation had RAP (71% of high-risk patients). We also found that patients 
with a high-risk genetic mutation had a 79% probability of having chronic pancreatitis. 
Thus, our findings are in agreement with prior studies that the presence of RAP or CP as 
opposed to a single attack of acute pancreatitis alone increases the chances of having a 
positive genetic test.
Pancreas divisum is more prevalent among patients with genetic abnormalities
Consistent with previous studies, we found a higher incidence of mutations among 
individuals with pancreas divisum. Previous studies reported high rates of CFTR (47–70%), 
PRSS1 (16%), and SPINK1 (16%) mutations among patients with CP and pancreas 
divisum.19–21 Therefore, pancreas divisum is an important phenotypic clue that a patient is 
at-risk for a genetic mutation (although the majority of patients with divisum were still 
negative for a mutation). Prior studies evaluating the effectiveness of minor papilla 
endotherapy in the setting of both RAP and pancreas divisum suggest that therapy is more 
beneficial in patients that have not yet developed chronic pancreatitis.39, 40 It should be 
noted that genetic testing was not evaluated in these studies and future work evaluating RAP 
and pancreas divisum should consider whether the presence of a genetic mutation correlates 
with response to minor papilla endotherapy.
Summary
Our study is limited by its retrospective design and potential for detection or recall bias, 
particularly when looking at issues such as family history. In addition, our study population 
included individuals with pancreatic disease who underwent genetic testing; therefore, the 
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treating physician suspected a genetic abnormality in all cases and so our results do not 
represent the prevalence of mutations in a general population of adults with pancreatic 
disease. Nevertheless, our observations are important since the sampling frame represents a 
“real-world” cohort of adults who are likely to undergo genetic testing. A history of RAP, 
CP and pancreas divisum increase the likelihood of a high-risk mutation, whereas the 
absence of a family history of RAP or CP does not rule out its possibility. Finally, the 
prevalence of both high-risk and any pancreas-specific mutation significantly increased with 
the use of complete gene sequence analysis. The clinical implications of this increase require 
further investigation.
In conclusion, patient characteristics that are associated with a pancreas-specific genetic 
mutation include a personal history of RAP, CP, family history of CP, and the presence of 
pancreas divisum. However, the majority of adults with a positive test had no significant 
family history. We have also shown that complete gene sequence analysis increases the 
probability of all and high-risk genetic mutations, keeping in mind that not all mutations 
have been characterized in terms of their clinical significance or association with 
pancreatitis. The potential clinical implications of identifying a genetic mutation are several: 
response to medical, surgical or endoscopic therapy may differ in this population, and 
physicians should push more aggressively for lifestyle modifications including smoking and 
alcohol cessation. Future prospective studies should evaluate differences in outcomes of 
individuals with pancreatic disease and genetic mutations, and specific medical therapies 
that compensate for genetic abnormalities are awaited.
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Abbreviations
CP chronic pancreatitis
RAP recurrent acute pancreatitis
CFTR cystic fibrosis transmembrane conductance regulator
PRSS1 protease serine 1
SPINK1 serine protease inhibitor, Kazal type 1
CTRC chymotrypsin C
CT computed tomography
MRI magnetic resonance imaging
EUS endoscopic ultrasound
ERCP endoscopic retrograde cholangiopancreatography
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MRCP magnetic resonance cholangiopancreatography
5′ UTR 5′ untranslated region
References
1. Keiles S, Kammesheidt A. Identification of CFTR, PRSS1, and SPINK1 mutations in 381 patients 
with pancreatitis. Pancreas. 2006; 33:221–7. [PubMed: 17003641] 
2. Truninger K, Malik N, Ammann RW, et al. Mutations of the cystic fibrosis gene in patients with 
chronic pancreatitis. Am J Gastroenterol. 2001; 96:2657–61. [PubMed: 11569691] 
3. Pezzilli R, Morselli-Labate AM, Mantovani V, et al. Mutations of the CFTR gene in pancreatic 
disease. Pancreas. 2003; 27:332–6. [PubMed: 14576497] 
4. Noone PG, Zhou Z, Silverman LM, et al. Cystic fibrosis gene mutations and pancreatitis risk: 
relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology. 2001; 
121:1310–9. [PubMed: 11729110] 
5. Weiss FU, Simon P, Bogdanova N, et al. Complete cystic fibrosis transmembrane conductance 
regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut. 2005; 
54:1456–60. [PubMed: 15987793] 
6. Audrezet MP, Chen JM, Le Marechal C, et al. Determination of the relative contribution of three 
genes-the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, 
and the pancreatic secretory trypsin inhibitor gene-to the etiology of idiopathic chronic pancreatitis. 
Eur J Hum Genet. 2002; 10:100–6. [PubMed: 11938439] 
7. Cohn JA, Friedman KJ, Noone PG, et al. Relation between mutations of the cystic fibrosis gene and 
idiopathic pancreatitis. N Engl J Med. 1998; 339:653–8. [PubMed: 9725922] 
8. Witt H, Luck W, Becker M. A signal peptide cleavage site mutation in the cationic trypsinogen gene 
is strongly associated with chronic pancreatitis. Gastroenterology. 1999; 117:7–10. [PubMed: 
10381903] 
9. Pfutzer RH, Whitcomb DC. Trypsinogen mutations in chronic pancreatitis. Gastroenterology. 1999; 
117:1507–8. [PubMed: 10610342] 
10. Schneider A, Barmada MM, Slivka A, et al. Clinical characterization of patients with idiopathic 
chronic pancreatitis and SPINK1 Mutations. Scand J Gastroenterol. 2004; 39:903–4. [PubMed: 
15513391] 
11. Drenth JP, te Morsche R, Jansen JB. Mutations in serine protease inhibitor Kazal type 1 are 
strongly associated with chronic pancreatitis. Gut. 2002; 50:687–92. [PubMed: 11950817] 
12. Threadgold J, Greenhalf W, Ellis I, et al. The N34S mutation of SPINK1 (PSTI) is associated with 
a familial pattern of idiopathic chronic pancreatitis but does not cause the disease. Gut. 2002; 
50:675–81. [PubMed: 11950815] 
13. Masson E, Chen JM, Scotet V, et al. Association of rare chymotrypsinogen C (CTRC) gene 
variations in patients with idiopathic chronic pancreatitis. Hum Genet. 2008; 123:83–91. [PubMed: 
18172691] 
14. Rosendahl J, Witt H, Szmola R, et al. Chymotrypsin C (CTRC) variants that diminish activity or 
secretion are associated with chronic pancreatitis. Nat Genet. 2008; 40:78–82. [PubMed: 
18059268] 
15. Cavestro GM, Zuppardo RA, Bertolini S, et al. Connections between genetics and clinical data: 
Role of MCP-1, CFTR, and SPINK-1 in the setting of acute, acute recurrent, and chronic 
pancreatitis. Am J Gastroenterol. 2010; 105:199–206. [PubMed: 19844201] 
16. Ockenga J, Stuhrmann M, Ballmann M, et al. Mutations of the cystic fibrosis gene, but not cationic 
trypsinogen gene, are associated with recurrent or chronic idiopathic pancreatitis. Am J 
Gastroenterol. 2000; 95:2061–7. [PubMed: 10950058] 
17. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with 
chronic pancreatitis. N Engl J Med. 1998; 339:645–52. [PubMed: 9725921] 
Ballard et al. Page 8
Pancreas. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
18. Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, 
Kazal type 1 are associated with chronic pancreatitis. Nat Genet. 2000; 25:213–6. [PubMed: 
10835640] 
19. Bertin C, Pelletier AL, Vullierme MP, et al. Pancreas divisum is not a cause of pancreatitis by 
itself but acts as a partner of genetic mutations. Am J Gastroenterol. 2012; 107:311–7. [PubMed: 
22158025] 
20. Garg PK, Khajuria R, Kabra M, et al. Association of SPINK1 gene mutation and CFTR gene 
polymorphisms in patients with pancreas divisum presenting with idiopathic pancreatitis. J Clin 
Gastroenterol. 2009; 43:848–52. [PubMed: 19593166] 
21. Choudari CP, Imperiale TF, Sherman S, et al. Risk of pancreatitis with mutation of the cystic 
fibrosis gene. Am J Gastroenterol. 2004; 99:1358–63. [PubMed: 15233679] 
22. Whitcomb DC. Framework for interpretation of genetic variations in pancreatitis patients. Front 
Physiol. 2012; 3:440. [PubMed: 23230421] 
23. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis–2012: revision of the 
Atlanta classification and definitions by international consensus. Gut. 2013; 62:102–11. [PubMed: 
23100216] 
24. Cote GA, Imperiale TF, Schmidt SE, et al. Similar efficacies of biliary, with or without pancreatic, 
sphincterotomy in treatment of idiopathic recurrent acute pancreatitis. Gastroenterology. 2012; 
143:1502–1509 e1. [PubMed: 22982183] 
25. Axon AT, Classen M, Cotton PB, et al. Pancreatography in chronic pancreatitis: international 
definitions. Gut. 1984; 25:1107–12. [PubMed: 6479687] 
26. Catalano MF, Sahai A, Levy M, et al. EUS-based criteria for the diagnosis of chronic pancreatitis: 
the Rosemont classification. Gastrointest Endosc. 2009; 69:1251–61. [PubMed: 19243769] 
27. Sugiyama M, Haradome H, Atomi Y. Magnetic resonance imaging for diagnosing chronic 
pancreatitis. J Gastroenterol. 2007; 42(Suppl 17):108–12. [PubMed: 17238038] 
28. Schlaudraff E, Wagner HJ, Klose KJ, et al. Prospective evaluation of the diagnostic accuracy of 
secretin-enhanced magnetic resonance cholangiopancreaticography in suspected chronic 
pancreatitis. Magn Reson Imaging. 2008; 26:1367–73. [PubMed: 18583078] 
29. Mosler P, Akisik F, Sandrasegaran K, et al. Accuracy of magnetic resonance 
cholangiopancreatography in the diagnosis of pancreas divisum. Dig Dis Sci. 2012; 57:170–4. 
[PubMed: 21761168] 
30. Lai R, Freeman ML, Cass OW, et al. Accurate diagnosis of pancreas divisum by linear-array 
endoscopic ultrasonography. Endoscopy. 2004; 36:705–9. [PubMed: 15280976] 
31. Quest L, Lombard M. Pancreas divisum: opinio divisa. Gut. 2000; 47:317–9. [PubMed: 10940261] 
32. Whitcomb DC. Genetic risk factors for pancreatic disorders. Gastroenterology. 2013; 144:1292–
302. [PubMed: 23622139] 
33. Whitcomb DC. Genetics of alcoholic and nonalcoholic pancreatitis. Curr Opin Gastroenterol. 
2012; 28:501–6. [PubMed: 22885947] 
34. Schneider A, Larusch J, Sun X, et al. Combined bicarbonate conductance-impairing variants in 
CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic 
fibrosis. Gastroenterology. 2011; 140:162–71. [PubMed: 20977904] 
35. Chang MC, Chang YT, Wei SC, et al. Spectrum of mutations and variants/haplotypes of CFTR and 
genotype-phenotype correlation in idiopathic chronic pancreatitis and controls in Chinese by 
complete analysis. Clin Genet. 2007; 71:530–9. [PubMed: 17539902] 
36. Montgomery J, Wittwer CT, Kent JO, et al. Scanning the cystic fibrosis transmembrane 
conductance regulator gene using high-resolution DNA melting analysis. Clin Chem. 2007; 
53:1891–8. [PubMed: 17890437] 
37. Sandhu B, Vitazka P, Ferreira-Gonzalez A, et al. Presence of SPINK-1 variant alters the course of 
chronic pancreatitis. J Gastroenterol Hepatol. 2011; 26:965–9. [PubMed: 21375584] 
38. Teich N, Bauer N, Mossner J, et al. Mutational screening of patients with nonalcoholic chronic 
pancreatitis: identification of further trypsinogen variants. Am J Gastroenterol. 2002; 97:341–6. 
[PubMed: 11866271] 
39. Lehman GA, Sherman S, Nisi R, et al. Pancreas divisum: results of minor papilla sphincterotomy. 
Gastrointest Endosc. 1993; 39:1–8. [PubMed: 8454127] 
Ballard et al. Page 9
Pancreas. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
40. Chacko LN, Chen YK, Shah RJ. Clinical outcomes and nonendoscopic interventions after minor 
papilla endotherapy in patients with symptomatic pancreas divisum. Gastrointest Endosc. 2008; 
68:667–73. [PubMed: 18436218] 
Ballard et al. Page 10
Pancreas. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. 
Schema: Adult individuals who underwent genetic testing for pancreas-specific mutations
* Defined as a heterozygous mutation of CFTR, CTRC or SPINK1
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Table 1
Summary of modalities for genetic testing used during the study period
Genetic Test CFTR PRSS1 SPINK1 CTRC
Ambry Genetics (Aliso Viejo, 
CA, USA)
DNA sequencing of 5′ UTR, 
27 exons, all introns, polyT 
status and TG repeats
DNA sequencing of 5′ 
UTR, exons 1–5 and all 
introns
DNA sequencing 
of 5′ UTR, exons 
1–4 and all introns
DNA sequencing 
of 5′ UTR, exons 
1–8 and all introns
Genzyme Corporation 
(Cambridge, MA, USA)
Enzymatic amplification of 
DNA for 97 mutations
Quest Diagnostics (Madison, 
NJ, USA)
Enzymatic amplification of 
DNA for 32 mutations
Mayo Clinic (Rochester, MN, 
USA)
DNA sequencing of exons 
2 and 3
University of Pittsburgh 
Medical Center (Pittsburgh, 
PA, USA)
DNA sequencing of exons 
2 and 3
5′ UTR = 5′ untranslated region
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Table 2
Probability of an abnormal genetic test
Gene mutation
Proportion with mutation P value¥¥¥
Complete Gene Sequencing (n=109)
N, (%)
Other tests (n=261)
N, (%)
Any mutation 46 (42.2%) 21 (8.1%) < 0.001
High-risk mutation 20 (18.3%) 4 (1.5%) < 0.001
PRSS1 (n=266)¥ 8 (7.5%) 3 (1.9%) 0.029
SPINK1 (n=107)¥ 15 (14.0%) N/A¥¥
CFTR (n=359)¥ 29 (26.6%) 20 (8.0%) <0.0001
CTRC (n=94)¥ 7 (7.5%) N/A¥¥
¥No patients were found to have a homozygous mutation
¥¥All patients who underwent testing for SPINK1 and CTRC mutations utilized complete gene sequencing.
¥¥¥
Fisher’s exact test
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